Elizabeth White
Adult Health · Hattiesburg, MSNPI 1184668584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$681
- Novo Nordisk$602
- Abbott$591
- Sanofi-aventis U.S. LLC$590
- Amgen$563
- Dexcom, Inc.$487
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,57899%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 42 | $681 |
| Novo Nordisk | 38 | $602 |
| Abbott | 34 | $591 |
| Sanofi-aventis U.S. LLC | 31 | $590 |
| Amgen(2 entities) | 36 | $563 |
| Dexcom, Inc. | 24 | $487 |
| Boehringer Ingelheim | 29 | $445 |
| Insulet Corporation | 4 | $241 |
| Pfizer | 13 | $222 |
| AbbVie | 13 | $210 |
| Bayer | 10 | $181 |
| AstraZeneca | 11 | $155 |
| Xeris Pharmaceuticals, Inc. | 5 | $117 |
| Novartis | 7 | $116 |
| Medtronic | 7 | $105 |
| Ascendis Pharma Endocrinology Inc | 4 | $70 |
| Tandem Diabetes Care, Inc. | 3 | $52 |
| Merck | 3 | $50 |
| GRT US Holding, Inc. | 3 | $44 |
| IBSA Pharma Inc. | 2 | $32 |
| Averitas Pharma Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Lifescan, Inc. | 1 | $14 |
How this compares
$5,641 in reported general payments places this provider in the 90th percentile of 93 adult health providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 337 | $452,643 |
| JardianceEmpagliflozin | 392 | $381,274 |
| OzempicSemaglutide | 277 | $287,672 |
| TrulicityDulaglutide | 112 | $141,576 |
| Tresiba Flextouch U-200Insulin Degludec | 126 | $128,006 |
| Tresiba Flextouch U-100Insulin Degludec | 192 | $124,552 |
| Novolog FlexpenInsulin Aspart | 240 | $84,484 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $67,797 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 119 | $57,786 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 33 | $55,364 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 95 | $54,752 |
| FarxigaDapagliflozin Propanediol | 60 | $39,690 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 198 | $39,397 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $36,136 |
| JanuviaSitagliptin Phosphate | 39 | $35,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $681 | $602,813489 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $445 | $407,639420 claims |
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $602 | $334,163375 claims |
| MerckJanuvia, Janumet Xr, Janumet | $50 | $54,77065 claims |
| AstraZenecaFarxiga | $155 | $39,69060 claims |
| Sanofi-aventis U.S. LLCLantus | $590 | $7,34044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 93 adult health providers in Mississippi.
Other adult health in Hattiesburg
- Jessica JonesHattiesburg$5K
- Amanda GreeneRidgeland$108K
- Rhonda HickmanTupelo$15K
- Angela SlaterFlorence$14K
- Jennifer Delaney-DavisOcean Springs$9K
- Traci EvansGulfport$8K
- Casey AdamsGulfport$8K
- Keila BrownJackson$7K
- Brandi JohnstonJackson$7K
- Deborah HoodJackson$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.